UCL researchers have developed an ultrasound helmet that enables deep brain stimulation without surgery, offering hope for Parkinson's and other neurological disorders.
George Atalla, EY Global Government & Infrastructure Leader, explores the effect that COVID-19 has had on the use of data and technology in healthcare.
Diffuse Intrinsic Pontine Glioma (DIPG) is an incurable childhood cancer that has no effective treatment - but now, scientists in Australia believe they have found a drug that could begin to treat this cancer.
The Lancet report is out today (11 February), which suggests that former President Trump's policymaking created an excess of "461,100 deaths" - before the COVID-19 pandemic hit the United States.
Researchers at the Medical College of Georgia have found a potential connection between the experience of unpredictable stress and the function of neurons that can trigger depression.
The legislative changes in the white paper released today (11 February) include giving local and central Government more control over the NHS - which is expected to be implemented in 2022.
The World Health Organisation have suggested that the Oxford and AstraZeneca vaccine can be safely used for all age groups, including those aged 65 and over.
New research by the American Heart Association finds that obesity is a factor in almost half of all new cases, with obese individuals significantly more likely to get Type 2 diabetes.
Edward Belgeonne, founder, & CEO Bantham Technologies, discusses how innovative technology is key to hitting net-zero and creating more time to care in the NHS.
The new results led to the South African Government suspending use of AstraZeneca in their vaccination programme, as it is no longer able to stop the mutation - but could still prevent hospitalisation and fatality.
Paul Barrett, TeleTracking UK, explains how automating patient flow and bed management in real-time can transform hospital operations, free up time for nurses to care, reduce stress on caregivers and importantly improve patient outcomes.
AstraZeneca dose efficiency holds at 76% in the three-month period between the first and second dose - suggesting that this time period is good for maximising protection.
Childhood air pollution has been understood as partially responsible for respiratory health - now, researchers are investigating at how exposure can damage cognitive ability later on in life.
